Acorda Therapeutics awarded $1M C-TRIP grant to aid research on GGF2 Acorda Therapeutics.

The first clinical research for GGF2 in patients with heart failing is expected to begin in mid-2010.D., Ph.D., Vice President of Preclinical Development at Acorda. NHLBI, a division of the National Institutes of Wellness , provides C-TRIP grants in order to advance analysis on promising new therapeutics that address unmet medical needs in cardiovascular diseases. The grant will support early phase GGF2 clinical research. If these research are successful, Acorda and Vanderbilt will be eligible to apply for a second phase C-TRIP grant of at least $7.5 million.Early surgery without preoperative biliary drainage did not increase the threat of complications, in comparison with preoperative biliary drainage, accompanied by surgery. The postoperative complication rate didn’t differ significantly between the two groups, as has been reported previously.26-29 With respect to complications related to endoscopic preoperative biliary drainage, the incidence of pancreatitis, perforation, or hemorrhage in our study was in accordance with the incidence reported by others.30-32 The rate of cholangitis associated with preoperative biliary drainage was high and an important reason for readmission. This high incidence of cholangitis was reported within the same range by all participating centers.

Copyright 2018